PER-057-15招募中未知
A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma.
CELLTRION, INC.,0 个研究点目标入组 4 人开始时间: 2016年4月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Each patient must meet all of the following criteria to be enrolled in this study: 1)Age ≥18 years.2)Histologically confirmed CD20+ FL grade 1 to 3a according to the World Health Organization 2008 classification.3)Has at least 1 measurable tumour mass in 2 dimensions:a)Nodal lesion >15 mm in the longest dimension; or b)Nodal lesion >10 mm to ≤15 mm in the longest dimension and >10 mm in the shortest dimension; or c) Extranodal lesion with both long and short dimensions ≥10 mm. 4)Ann Arbor stage II, III, or IV disease.5)Low tumour burden, defined as based on Groupe d´Etudes des Lymphomes Folliculaires (GELF) criteria.6) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.7)Male and female patients and their partners of childbearing potential, patient agrees to practice total abstinence or to use one of the following medically acceptable methods of contraception during the course of the study and for 12 months following discontinuation of study drug.8) Adequate bone marrow, hepatic, and renal function reserve as evidenced by:a)Hb ≥10 g/dL, b)Absolute neutrophil ≥1500/mm3,c)Platelet ≥100 000/mm3,d)Total bilirubin ≤2.0 mg/dL, e)Aspartate aminotransferase and alanine aminotransferase ≤3 times the upper limit of normal (ULN) for the reference laboratory (≤5 × ULN for the reference laboratory with known hepatic involvement by lymphoma), f)Serum creatinine ≤1.5 × ULN for the reference laboratory, or a calculated creatinine clearance by the Cockcroft-Gault equation of ≥50 mL/min.9)Patient is able to understand instructions and comply with all study requirements.10)Patient is informed, given ample time and opportunity to read and/or understand about participation in the study, and has signed and dated the written ICF.
排除标准
- •Patients meeting any of the following criteria will be excluded from the study:1)Has received rituximab (or a biosimilar product).2)Allergies or hypersensitivity to contrast agents for radiograph, murine, chimeric, human or humanised proteins.3)Evidence of histological transformation to high-grade or diffuse large B cell lymphoma.4))Known central nervous system involvement or any evidence of spinal cord compression by lymphoma.5)Has received previous treatment for NHL.6)Current diagnosis of active tuberculosis or other severe infections, such as sepsis, abscesses, or opportunistic infections.7)Infection with human immunodeficiency virus; hepatitis B or C.8)New York Heart Association class III or IV heart failure, severe uncontrolled cardiac disease, or myocardial infarction within the previous 6 months before the first administration of the study drug.9)Any malignancy other than NHL, except adequately treated squamous or basal cell carcinoma of the skin or cervical carcinoma in situ, within the 5 years before the first administration of the study drug.10)Current or recent treatment with any other investigational medicinal product or device.11)Uncontrolled diabetes mellitus, even after insulin treatment.12)Is pregnant or lactating. Patients who are planning to be pregnant or to breastfeed before, during, or within 12 months after the last administration of the study drug are not permitted to enrol into the study.13)Is taking a live, live-attenuated, or nonlive vaccine within 4 weeks before the first administration of the study drug.14)Evidence of any other coexisting disease or medical or psychological condition, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational product, or patient is high risk for treatment complications.
研究者
相似试验
进行中（未招募）
1 期
A Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphomaow Tumour Burden Follicular Lymphoma.MedDRA version: 20.0 Level: PT Classification code 10065856 Term: Non-Hodgkin's lymphoma unspecified histology indolent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005324-10-CZCELLTRION, Inc.250
进行中（未招募）
1 期
A Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphomaow Tumour Burden Follicular Lymphoma.MedDRA version: 20.0Level: PTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005324-10-PTCELLTRION, Inc.258
进行中（未招募）
3 期
A study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular LymphomaCTRI/2016/01/006493CELLTRION Inc
进行中（未招募）
1 期
A Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphomaow Tumour Burden Follicular Lymphoma.MedDRA version: 18.0 Level: PT Classification code 10065856 Term: Non-Hodgkin's lymphoma unspecified histology indolent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005324-10-ESCELLTRION, Inc.118
进行中（未招募）
1 期
A Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular LymphomaEUCTR2014-005324-10-LVCELLTRION, Inc.118